PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2017New England Journal of Medicine1,416 citationsOpen Access

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

View Full Paper
GMGϋnter von MinckwitzMPMarion ProcterEAEvandro de Azambuja

Key Points

  • To evaluate the efficacy and safety of adding pertuzumab to adjuvant trastuzumab and chemotherapy in patients with operable HER2-positive early breast cancer.
  • Randomized, placebo-controlled clinical trial (APHINITY, NCT01358877) evaluating adjuvant pertuzumab versus placebo in combination with trastuzumab and chemotherapy.
  • The study population comprised patients with operable HER2-positive breast cancer.
  • Pertuzumab significantly improved the rates of invasive-disease-free survival compared with placebo when added to standard adjuvant trastuzumab and chemotherapy.
  • Diarrhea occurred at a higher frequency in patients receiving pertuzumab than in those receiving placebo.

Abstract

Pertuzumab significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy. Diarrhea was more common with pertuzumab than with placebo. (Funded by F. Hoffmann-La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877 .).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Minckwitz et al. (2017) studied this question.

synapsesocial.com/papers/69d56e3375589c71d767d4d5https://doi.org/10.1056/nejmoa1703643
Ask AI
Helpful
Bookmark
Share
View Full Paper